Product Description
Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. Atamestane is highly effective in inhibiting estrogen-induced hyperplastic changes in the fibromuscular stroma of the prostate in androstenedione-treated dogs and monkeys. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1722797/)
Mechanisms of Action: ARO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Intarcia
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00044291 |
Biomed 777-CLP-29 | P3 |
Completed |
Breast Cancer |
2006-01-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT00010322 |
CDR0000068480 | P3 |
Terminated |
Breast Cancer |
2001-05-01 |
2025-02-07 |
Treatments |
|
NCT00267553 |
Biomed 777-CLP-32 | P3 |
Terminated |
Breast Cancer |
None |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT00097344 |
The CAT Study | P3 |
Terminated |
Breast Cancer |
None |
2025-02-07 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|